RT Journal Article
SR Electronic
T1 Integrated miRNA/cytokine/chemokine profiling reveals immunopathological step changes associated with COVID-19 severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.04.21261471
DO 10.1101/2021.08.04.21261471
A1 Wilson, Julie C.
A1 Kealy, David
A1 James, Sally R.
A1 Newling, Katherine
A1 Jagger, Chris
A1 Filbey, Kara
A1 Mann, Elizabeth R.
A1 Konkel, Joanne E.
A1 Menon, Madhvi
A1 Knight, Sean B.
A1 Simpson, Angela
A1 ,
A1 Grainger, John R.
A1 Hussell, Tracy
A1 Kaye, Paul M.
A1 Signoret, Nathalie
A1 Lagos, Dimitris
YR 2021
UL http://medrxiv.org/content/early/2021/08/05/2021.08.04.21261471.abstract
AB Circulating microRNAs (miRNAs) are exceptional mechanism-based correlates of disease, yet their potential remains largely untapped in COVID-19. Here, we determined circulating miRNA and cytokine and chemokine (CC) profiles in 171 blood plasma samples from 58 hospitalised COVID-19 patients. Thirty-two miRNAs were differentially expressed in severe cases when compared to moderate and mild cases. These miRNAs and their predicted targets reflected key COVID-19 features including cell death and hypoxia. Compared to mild cases, moderate and severe cases were characterised by a global decrease in circulating miRNA levels. Partial least squares regression using miRNA and CC measurements allowed for discrimination of severe cases with greater accuracy (87%) than using miRNA or CC levels alone. Correlation analysis revealed severity group-specific associations between CC and miRNA levels. Importantly, the miRNAs that correlated with IL6 and CXCL10, two cardinal COVID-19-associated cytokines, were distinct between severity groups, providing a novel qualitative way to stratify patients with similar levels of proinflammatory cytokines but different disease severity. Integration of miRNA and CC levels with clinical parameters revealed severity-specific signatures associated with clinical hallmarks of COVID-19. Our study highlights the existence of severity-specific circulating CC/miRNA networks, providing insight into COVID-19 pathogenesis and a novel approach for monitoring COVID-19 progression.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the UKRI MRC/NIHR award to the UK Corovanirus Immunology Consortium (UK-CIC, MR/V028448/1). Sample collection was supported by the NIHR Manchester Biomedical Research Centre (TH and AS) and 3M Global Giving award (JRG and TH). JRG is supported by a senior fellowship by The Kennedy Trust for Rheumatology Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Individuals with COVID-19 were recruited from 3 hospitals in the Greater Manchester area, Manchester University Foundation Trust (MFT), Salford Royal NHS Foundation Trust (SRFT) and Pennine Acute NHS Trust (PAT) under the framework of the Manchester Allergy, Respiratory and Thoracic Surgery (ManARTS) Biobank (study no M2020-88) for MFT or the Northern Care Alliance Research Collection (NCARC) tissue biobank (study no. NCA-009) for SRFT and PAT. Ethics approval was obtained from the North West-Haydock Research Ethics Committee for ManARTS (reference 15/NW/0409) and from the Wales Research Ethics Committee 4 for NCARC (reference 18/WA/0368).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available.